Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT03170960 : A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Bowel (colorectum),Breast,Female reproductive organs,Head and neck,Lung,Stomach and upper gastrointestinal tract,Urinary systemBladder,Breast,Colon,Colorectum,Gastro-oesophageal junction ,Head and neck,Kidney,Liver,Lung,Non-Small Cell Lung Cancer,Ovary,Prostate,Rectum,Renal cell carcinoma,Stomach,Thyroid,Urothelial

Trial Overview Read MoreRead more

This phase Ib trial is trying to understand how safe and tolerable a type of targeted therapy is for the treatment of several different types of cancer.
 

This trial is treating multiple types of cancer including advanced urothelial carcinoma (UC), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer/gastroesophageal junction cancer/lower esophageal cancer, colorectal cancer (CRC), head and neck (H&N) cancer, and differentiated thyroid cancer (DTC).

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Commercial Sponsor

Exelixis

Summary

This is a dose escalation and expansion study. In the dose escalation phase, eligible patients will be assigned to receive either 20mg, 40mg or 60mg of oral cabozantinib in combination with a standard dose of atezolizumab. Patients enrolled in the expansion phase will be assigned to a relevant cohort based on their diagnosis and treatment history, and will receive a recommended phase 2 dose of cabozantinib in combination with atezolizumab.

Recruiting Hospitals Read MoreRead more

Western Health - Sunshine Hospital
St Albans
Ms Heike Raunow
CancerClinicalTrials@wh.org.au
0434 915 739

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next